Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback